Microphyt
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Microphyt - overview
Established
2007
Location
-, -, France
Primary Industry
Materials
About
Based in France, Microphyt specializes in developing and marketing microalgae-based natural ingredients aimed at the nutrition and beauty sectors, leveraging biotechnology to create innovative health solutions. Microphyt, founded in 2007 in France, focuses on creating high-value microalgae-based products. The company has successfully raised EUR 15. 04 mn in its Series B funding round in December 2022, led by L'Oréal BOLD Ventures and supported by prominent investors including Bpifrance and Sofinnova Partners.
The CEO of Microphyt is Vincent Usache. Microphyt specializes in developing and marketing microalgae-based natural ingredients primarily for the nutrition and beauty sectors. The company's core product offerings include bioactive compounds that leverage unique microalgae diversity to create innovative solutions for health and well-being. Notable products include Luteana™, which enhances scalp health, and DunaPure™, targeting skin imperfections.
Microphyt serves various industries including nutraceuticals and cosmetics, primarily in Europe, North America, and Asia, with an emphasis on eco-efficient solutions that align with contemporary consumer demands. In the most recent year, 2021, Microphyt generated revenue of EUR 846,111. 4, though it recorded an EBITDA loss of EUR 2,040,867. 6.
With the EUR 15. 04 mn raised in the Series B funding round in December 2022, Microphyt plans to accelerate the development of eco-designed ingredients and enhance its production capabilities. This funding will support the introduction of new products and expand their presence in existing markets, particularly targeting growth in North America and Asia by 2024.
Current Investors
Sofinnova Partners, Demea Invest, IXO Private Equity
Primary Industry
Materials
Sub Industries
Biomaterials
Website
www.microphyt.eu
Verticals
Research (Non-Medical)
Company Stage
Series B
Total Amount Raised
Subscriber access only
Microphyt - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 145,933 | 69,752 | 245,188 | 272,079 | 216,863 | 715,229 | - | - | - |
| % Revenue Growth (YoY) | - | (52.2%) | 251.5% | 11.0% | (20.3%) | 229.8% | - | - | - |
| EBITDA (USD) | (282,319) | (273,698) | (269,895) | (1,044,558) | (2,247,481) | (1,725,172) | - | - | - |
| Operating Income (USD) | (398,454) | (396,393) | (401,340) | (1,199,287) | (2,789,187) | (2,139,031) | - | - | - |
| Operating Margin | (273.0%) | (568.3%) | (163.7%) | (440.8%) | (1286.2%) | (299.1%) | - | - | - |
| % EBITDA Margin | (193.5%) | (392.4%) | (110.1%) | (383.9%) | (1036.4%) | (241.2%) | - | - | - |
| NET Income (USD) | (165,794) | (154,095) | 46,670 | (1,085,250) | (2,436,078) | (3,250,199) | - | - | - |
| % Net Margin | (113.6%) | (220.9%) | 19.0% | (398.9%) | (1123.3%) | (454.4%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.